Your browser doesn't support javascript.
loading
Optimization of 7,12-dimethylbenz(a)anthracene-induced rat epithelial ovarian tumors.
Yang, Xiu Ying; Li, Ying; Cai, Song Qi; Wang, Li; Qiang, Jin Wei.
Afiliación
  • Yang XY; Department of Radiology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China.
  • Li Y; Department of Radiology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China.
  • Cai SQ; Departments of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
  • Wang L; Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China.
  • Qiang JW; Department of Radiology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China.
Oncol Lett ; 21(3): 206, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33574945
Ovarian carcinoma is the second most common malignant tumor of the female reproductive system and an notable cause of cancer death. The detection and diagnosis of early ovarian carcinomas are still clinical challenges, which calls for imaging studies using early ovarian carcinoma animal models. The present study aimed to optimize the 7,12-dimethylbenz(a)anthracene (DMBA)-induced model of rat ovarian tumors by investigating the delivery methods, induction dose and time of DMBA exposure, and explored the morphological features of tumors using MRI. Three schemes were performed. In scheme one the ovary was covered with absorbable hemostatic gauze loaded with a high concentration of liquid DMBA. For this scheme, 150 Sprague-Dawley rats were divided into three groups depending on the DMBA dose (1.0, 2.0 and 3.0 mg). In scheme two DMBA solution was injected under the ovarian capsule. For this scheme, 159 rats were divided into 0.5, 1.0 and 1.5 mg DMBA groups. In scheme three the ovary was covered with absorbable gauze loaded with a high concentration of solid DMBA. For this scheme 161 rats were divided into 1.0, 2.0 and 3.0 mg DMBA groups. Each group of the three schemes was further subdivided into 60-, 90-, 120-, 150- and 180-day groups. In scheme two, the tumor formation rate was 75.6% (99/131), which was the highest in the 1.5 mg group (86.4%, 38/44) and reached 100% (10/10) on day 120. The induced tumors were serous in 93.9% (93/99) of tumors. Borderline ovarian tumors accounted for 19.2% (19/99) of all tumors, and ovarian cancer accounted for 46.5% (46/99). The mean maximum diameter (MMD) of borderline ovarian tumors was 10.29±3.41 mm, and that of ovarian cancer was 15.19±7.10 mm. MMD of the solid components increased with increasing malignancy. Cystic, cystic-solid and solid tumors were observed. The ovarian subcapsular injection of 1.5 mg DMBA was the best scheme for the rat ovarian tumor model. The present model is ideal for investigating the occurrence, development and imaging of ovarian tumors.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Lett Año: 2021 Tipo del documento: Article Pais de publicación: Grecia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Lett Año: 2021 Tipo del documento: Article Pais de publicación: Grecia